Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
aLT-803 promotes innate-like CD8 + T-cell effector activity and ...
First-in-human phase 1 clinical study of the IL-15 superagonist complex ...
ALT-803, an IL-15 superagonist, in combination with nivolumab in ...
(PDF) The IL-15-based superagonist ALT-803 promotes the antigen ...
CD8 þ T-cell production of IFN-g plays a role in ALT-803– | Download ...
(PDF) The IL-15 superagonist ALT-803 enhances anti-CD20 antibody ...
ALT-803: IL-15 Superagonist Complex Fact Sheet
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer ...
Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and ...
Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15 ...
Figure 1 from A Novel Fusion of ALT-803 (Interleukin (IL)-15 ...
Effectiveness of two different dose administration regimens of an IL-15 ...
The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK ...
Therapeutic administration of IL-15 superagonist complex ALT-803 leads ...
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell ...
Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads ...
(PDF) IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits ...
(PDF) An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell ...
Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly ...
ASCO GU 2021: Phase II/III Clinical Results of IL-15RαFc Superagonist N ...
Targeted IL-15-based Protein Fusion Complexes as Cancer Immunotherapy ...
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell ...
(PDF) Enhanced efficacy of ALT-803, an IL-15-based superagonist complex ...
(PDF) Targeted IL-15-based Protein Fusion Complexes as Cancer ...
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells ...
(PDF) Combination therapy of an IL-15 superagonist complex, ALT-803 ...
Frontiers | IL-15 in the Combination Immunotherapy of Cancer
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective ...
Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination ...
An IL-15-based superagonist ALT-803 enhances the NK cell response to ...
Rawad Elias on Twitter: "The IL-15 #Superagonist #ALT-803 by ...
(PDF) IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL ...
The IL-15-based ALT-803 complex enhances FcγRIIIa-triggered NK cell ...
Efficacy and mechanism-of-action of a novel superagonist interleukin-15 ...
Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist ...
ALT-803 stimulation of human NK cells enhances lytic activity against ...
(PDF) The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T ...
ALT-803 did not increase expression maturation markers on BM dendritic ...
Figure 1 from First-in-human phase 1 clinical study of the IL-15 ...
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an ...
Evaluation of the biological activities of the IL-15 superagonist ...
ALT-803 enhances NEO-201-mediated ADCC against human carcinoma cell ...
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients ...
Heterodimeric IL-15 in Cancer Immunotherapy
Immune cell effects on the antimyeloma activity of ALT-803. A, female ...
(PDF) Enhanced efficacy of IL-15-based ALT-803 superagonist complex in ...
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc ...
Comparison of the super agonist complex, ALT-803, to IL-15 as cancer ...
AUA 2019: Preliminary Phase 2 Results of IL-15RαFc Superagonist N-803 ...
Full article: The IL-15-based superagonist ALT-803 promotes the antigen ...
Frontiers | ALT-803 in the treatment of non-muscle-invasive bladder ...
(PDF) Comparison of the Superagonist Complex, ALT-803, to IL15 as ...
(PDF) A novel fusion of ALT-803 (IL-15 Superagonist) with an antibody ...
PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX ...
Table 1 from First-in-human phase 1 clinical study of the IL-15 ...
(PDF) Effectiveness of two different dose administration regimens of an ...
